Guidelines for deprescribing PPIs suggest that adults with upper GI symptoms who have completed a minimum 4-week course of PPI treatment, resulting in resolution of upper GI symptoms, can decrease the daily dose or stop and change to on-demand use. Deprescribing guidelines do not include patients with Barrett esophagus, severe esophagitis (grade C or D), or documented history of bleeding GI ulcers. Guidelines suggest consideration of PPI use in patients who require both an SSRI and NSAID, if the patient has other risk factors for upper GI ulceration or bleeding.
This Fast Five Quiz was excerpted and adapted from the Medscape Drugs & Diseases article Gastroesophageal Reflux Disease.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: B.S. Anand. Fast Five Quiz: Gastroesophageal Reflux Disease (GERD) - Medscape - Jul 29, 2021.